• Company has completed steps necessary to achieve, sustain competitive advantage in move towards remote-health solutions and trials
• RYAH technology optimizes patient feedback so medical trials, studies can move into remote solution zones
• Recently developed an integrated, customized mobile application to support a major clinical study in the United Kingdom
• RYAH created cloud of stored data to help with R&D of future medical treatments

RYAH Group, a leading digital health-care analytics and technology company, is on a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. The company believes that, when patients are given more control overdosing, doctors can offer personalized treatment plans based on collective information.

Accenture, a global professional service company, recently surveyed 128 life science industry leaders to better understand digital transformation in the lab. The survey results revealed the following three key steps, which life science companies must take in order to achieve and sustain a competitive advantage in a world with enormous amounts of data to sift through (https://ibn.fm/ZQ3uz):

• Lay the groundwork with automation, connecting all instruments and digital data capturing
• Move toward a cloud-based, multivendor platform with enhanced security, data access, instrument integration and more with analytics powered insights to enhance workflow and compliance
• Create and power an end-to-end data supply chain, deeper adoption of AI, with whole lab automation and implementation

RYAH is meeting each of these steps head-on by creating useful technology that collects, analyzes and leverages objective data on therapeutic plant usage. Patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time. The patient controls the process, and the instruments that collect digital data remain anonymous.

When patient feedback is optimized, medical trials and studies can move into remote solution zones. RYAH has recently developed a custom solution where a patient session temperature and dosing is set and locked by the clinical partner, suitable for both medium- and large-scale studies.

In 2013 the FDA suggested a shift to remote monitoring (https://ibn.fm/3pr60), but the industry has been slow to adopt the necessary technology — until COVID-19 made it nearly impossible to conduct traditional monitoring. In today’s pandemic setting, more clinical trials are needed that connect patients and researchers without the need for in-person monitoring or unnecessary risk to exposure.

Communication between the monitor and the patient is essential. Notifications, in-app messaging and push notifications help create personalized plans for patients, tailored to their unique conditions and tolerance of the treatment.

RYAH is focused on expanding the understanding of proprietary technology that supports a data-driven approach to positively impact patients’ future treatment for various medical conditions. By coupling a anonymous database with AI, the company has created a cloud of stored data to help with the R&D of future medical treatments. RYAH is actively making digital transformation in the lab a reality, paving the way forward for a medical future with remote solutions.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• Both heart disease, poor metabolic health increase complications of COVID-19, according to health professionals
• HYB Holding Corp. offers cloud-based software that transforms analog ultrasound 2D images into a digital 3D HD formats that quantify diagnostic capabilities
• Software can be used to enhance ultrasound images of vital organs, tendons, skin, nerves for use across multiple healthcare markets
• Provisional patent filed with U.S. Patent and Trademark Office

Epidemiologists observed that people with cardiovascular disease were more than twice as likely to contract severe forms of COVID-19 (https://ibn.fm/wG2j4). HYB Holding (OTC: HYBG), through its Mediscan Inc. subsidiary, offers imaging solutions to ultrasound professionals through cloud-based software that reconstructs analog 2D grayscale visual images into digital 3D high-definition quantifiable formats that can address the critical need to monitor COVID-19 patients for cardiac damage.

While death rates from COVID-19 have dropped significantly in the last six months, cardiovascular disease continues to remain a major predictor of poor outcome. HYBG’s Mediscan software application helps ultrasound technicians derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma while facilitating support for treatment options. The software additionally enables health professionals to monitor the patient’s ongoing progress or regress while documenting compliance with required protocols and procedures.

The company’s software specifically transforms ultrasound analog 2D grayscale images into digital 3D HD format that helps technicians derive data-driven insights into the condition of a patient.  Along with vital organs like the heart, the technique can generate 3D medical images of other parts of the body such as the lungs, tendons, skin and nerves for analysis by emergency medical services (EMS) and other health professionals such as primary care physicians, specialists, technical support staff and sports trainers.

The software is cloud-based and easy to use anywhere there is an internet connection, providing point-of-service medical professionals comparable image quality of CT or X-ray but without the radiation risk and at a far lower cost. Besides upgrading services for healthcare professionals, Mediscan software provides a convenient and comfortable medical experience for patients.

The company plans to make the software available as medical software-as-a-service (SaaS), a widely-used model in the health care industry for clinical information systems, supply chain management, revenue cycle management and billing. Along with operational cost-savings, the SaaS model eliminates the need for external hardware and software configurations as well as technical onsite maintenance. HYBG has a patent application filed with the United States Patent and Trademark Office through its Mediscan subsidiary for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

Flexible and easy-to-use, portable ultrasounds equipped with Mediscan’s application empower health care providers to evaluate, triage and diagnose the effects of heart disease on COVID-19 patients. The increasing demand for early diagnosis and the widening scope of clinical applications create a promising opportunity for Mediscan to fulfill its mission of developing and distributing medical imaging solutions to both long-term care facilities and acute and emergency medical services.

For more information, visit the company’s website at www.MyMediScan.com.

NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

• CBD-based products have become increasingly popular among professional athletes, primarily due to pain-relieving, anti-inflammatory qualities
• CannAssist International’s Xceptor Labs is an active player within the CBD-based product sector through the development of its proprietary CiBiDinol technology
• CiBiDinol’s technology, using a water-soluble carrier, developed an encapsulation process to deliver unchanged CBD molecule through cell’s watery matrix
• Xceptor Labs has seen rapid uptake in products’ popularity, with ten products now available for sale online

When three-time National Football League tight end Rob Gronkowski first announced his retirement from professional football, he attributed part of the decision to the heavy toll that injuries and nine subsequent surgeries had had on his ravaged body. However, the use of cannabidiol (“CBD”)-based topical pain relief products and the significant benefit provided by these played a large part in influencing the Super Bowl-winning athlete to return to the professional sports arena. CannAssist International (OTCQB: CNSC), a biotechnological pharmaceutical company and owner of Xceptor Labs, has sought to capitalize on the growing prominence CBD-based products within professional sports through its innovative technology and proprietary product portfolio. The chronic use of over-the-counter pain relievers (i.e., nonsteroidal anti-inflammatory drugs or NSAIDs) and opioids are widely documented as posing more significant health risks previously known, with opioid addictions leading to the deaths of thousands of Americans annually. In such a landscape, professional athletes have been eager to learn about the pain relief and inflammation-reducing qualities found in CBD products while forgoing the risks commonly associated with NSAIDs or opioids. The interest in CBD for pain alleviation has only gained further momentum following the World Anti-Doping Agency (“WADA”) and the US Anti-Doping Agency (“USADA”) ‘s joint decision to remove CBD from their list of prohibited substances – in or out of competition (https://ibn.fm/8aXyt). In a sector that has seen its ranks rapidly swell given an influx of new entrants, CannAssist’s wholly-owned Xceptor Labs has sought to differentiate itself through the use and development CiBiDinol technology. CiBiDinol’s technological make-up is a proprietary process specifically designed to address a number of the shortcomings currently afflicting oil-soluble CBD molecules. These advantages in delivery, bioavailability and short shelf-life (https://ibn.fm/uigze) have been verified with third-party testing habitually demonstrating a 300% increase in gut absorption rate and a 400% increase in skin penetration for CiBiDinol relative to regular oil-based CBD (https://ibn.fm/n0x1m). Perhaps more critically, the product’s effective absorption has also allowed for lower dosage requirements, thereby significantly lowering the amount of CBD needed to achieve its targeted endpoints. In September 2020, Xceptol brand pain creams containing CiBiDinol were released; each cream carries FDA-registered ingredients, designed to provide localized fast-acting relief for sore, aching muscles and joints. In December 2020, the company added seven more SKU’s that include capsules and drops; Xceptol’s full range of consumer products is now available on www.xceptol.com and www.RangeMe.com, a site dedicated to vetting brands for large retailers. “This is exciting news for us on many fronts; a process estimated to take weeks we accomplished in a few days – a testament, I feel, to the quality of the Xceptol brand,” noted CannAssist CEO Mark Palumbo regarding the news. “Also gratifying is being included on the RangeMe website, a significant portal for major retailers to find products for their customers.” The global CBD industry is set to rise from a market value of $4.6 billion in 2018 to an estimated $23.6 billion by 2025 (https://ibn.fm/SI4g6), CannAssist International seems advantageously positioned to benefit from the ongoing upswell in interest in CBD. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Golden Leaf Holdings Ltd. is licensed in Oregon and Nevada, with partnerships in manufacturing and distribution in California
• The Chalice Brands offer full lines of cannabis products grown organically and by local growers
• The company offers production, processing, wholesale distribution and retail operations within the cannabis industry
• Golden Leaf Holdings reported sales growth during the pandemic, recording revenue of $6.2 million in Q3 2020, an increase of 42% from Q3 2019. At the end of the third quarter, the company had exceeded total fiscal 2019 revenues
• The cannabis market is forecast to achieve a CAGR of 18.1%, climbing to a value of $73.6 billion by 2027

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF) is a premier consumer-driven cannabis company powered by the Chalice retail and consumer brands. GLH takes a diversified approach to growth through innovation, strategic partnerships and retail expansion, as well as a brand portfolio focusing on health and wellness. The company features best in class retail cannabis experiences backed by cultivation, processing and developing wholesale distribution. With over 160 employees, GLH is one of the largest cannabis operators in Oregon. The company holds licensing in Oregon, as well as partnerships for manufacturing and distribution in California. Its current product portfolio includes recognizable brands such as Chalice(TM), Elysium Fields(TM), GOLDEN(TM), Jackpot(TM) and RXO(TM). Brands Golden Leaf Holdings offers an innovative product line that addresses current market needs and looks forward to meet emerging trends. The company’s goal is to offer something for everyone through the wholesale and retail marketplaces. Its current product offerings include: Chalice(TM) The Chalice Farms(TM) brand is focused on how cannabis enhances lives and ignites purpose. By offering the highest quality of cannabis in an array of flower, extracts, oils, edibles and full-body care products, the brand provides full efficacy in both the retail and wholesale markets. The Chalice Farms team has over 100 years of combined cannabis experience and continues to be an industry leader for both medical and recreational cannabis use – providing state-of-the-art farming practices, excellent retail and complete product innovation. Elysium Fields(TM) Elysium Fields(TM) is a “soil-to-oil” craft cannabis brand intended for cannabis connoisseurs who want the highest quality THC and boldest terpene flavors. Made from small-batch live resin, Elysium Fields creates an experience described as a remarkable entourage effect. The C-Cell cartridge has a 30% strain specific HTE with a 70% high THC distillate. The resin is created from a sustainable, organic garden flower that is flash-frozen upon harvest to preserve the terpenes for a heavenly experience. RXO(TM) RXO(TM) features Chalice Farms’ purest and most versatile Rick Simpson Oil products. RXO was developed by the Steele brothers in collaboration with medical professionals and is a potent, strain-specific Ethanol Hash Oil (“EHO”) purified through a proprietary process. Through this process, various consumption methods can be accommodated, including edible, topical, sublingual and smoking (shatter and vape). GOLDEN(TM) GOLDEN(TM) offers a wide variety of craft cannabis products for a diverse population of cannabis users. Sourced from the finest raw materials from local growers, GOLDEN products are high-quality and innovative. Premium cannabis distillate vaporizer cartridges and fruit chew edibles made from organic ingredients are made using the most flavorful terpenes for enhanced health, wellness and enjoyment. Products are distributed online and through Chalice Farms or other dispensary partners. Jackpot(TM) Jackpot(TM) products offer a powerful combination of flavor and potency. With 70% THC content in each cartridge, Jackpot adds full-spectrum cannabinoids and flavorful infused terpenes in short-run limited strains for on-the-go fun seekers. The quality hardware of the cartridges makes them easily recyclable and guarantees to produce a large volume draw each time. Cannabis Market Outlook In 2020, the legal cannabis market was valued at approximately $23 billion, and it is expected to top $73.6 billion in revenue by 2027, growing at a CAGR of 18.1% during the forecast period (https://ibn.fm/LdkhG). One of the biggest factors driving the cannabis market’s growth is legalization around the world. As cannabis sales generally increased during the pandemic, Golden Leaf Holdings achieved record financials for Q3 2020, reporting quarterly revenue of $6.2 million, a year-over-year increase of 42%. For the first time in its history, the company also reported positive cash flow in excess of $417,000 (https://ibn.fm/LY1b2). Golden Leaf Holdings is uniquely positioned to capitalize on the growth of both the medicinal and recreational marijuana market segments through a rich product offering that successfully addresses current consumer needs. Management Team Jeff Yapp is the CEO and President of Golden Leaf Holdings Ltd. He has created a culture at GLH that operates under his mantra of ‘Crawl, Walk, Run’. He is an accomplished entrepreneur and corporate executive who has built a successful career through his ability to recognize opportunity, even when it isn’t obvious. Mr. Yapp has an extensive background in retail, marketing and entertainment. In the past, he has been committed to bringing innovation to Fortune 25 companies such as Microsoft, Kraft Foods, PepsiCo and more. As a strategic partner for Microsoft, he is an integral driver of growth for online and retail operations. He graduated with honors from the University of Michigan, majoring in Business Administration. He also graduated with honors from JL Kellogg School of Management at Northwestern University. John Varghese is the Executive Chair of Golden Leaf Holdings and is responsible for all capital markets initiatives at GLH. His background is in mergers and acquisitions, investing, operations and capital markets, with professional experience that ranges from private equity, venture capital and investment banking to senior management positions and director roles in both private and public companies. He has served on over 20 boards, acting as the chairman of six of them. Andrew Marchington is the company’s CFO. His public accounting career experience includes time with start-up, high-growth and enterprise-level organizations, including five years of prior cannabis industry experience. He has a rich understanding of the priorities and best practices within accounting, finance and management. Mr. Marchington’s past experience includes time with companies like Deloitte, Moss Adams, Cambia Health Solutions and C21 Investments. John Ford, Golden Leaf Holdings’ Chief Revenue Officer and VP of Retail, is a seasoned and dynamic retail leader with extensive experience in the retail industry who has led the launch of major retail brands such as Apple and Microsoft in China and Australia. His goal is to help retailers transition their businesses to modern experiential locations where customers can engage with products and brands in new ways. At Apple, Mr. Ford was the only field expat sent to launch Apple Retail in China. He set several records for Apple while in China, not just in sales but also in inventory management and employee turnover. Mr. Ford left Apple to lead Microsoft’s international retail expansion, where he also managed its e-commerce presence. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

• Powerfully diverse Chinese social media and entertainment conglomerate Momo is finding a measure of renewed optimism following a pandemic-delivered economic blow to its businesses during the past year
• Momo operates social connectivity services, online dating facilitation and TV and radio production interests
• The company’s social connection streams provide a useful service during the social distancing strictures imposed by governments striving to contain the spread of the COVID-19 virus
• Momo has seen a positive response to changes in its top leadership during the past year as part of its efforts to redefine its strategy

Chinese mobile-based social networking giant Momo Inc. (NASDAQ: MOMO) continues to regain momentum from COVID pandemic-induced difficulties during the past year, seeing new options become available (https://ibn.fm/nI0JK), share prices rise (https://ibn.fm/772H8) and its appeal increasing generally with investors (https://ibn.fm/KMArq) during recent weeks.

Momo has operated in three primary service line segments since its launch in 2011 and its Nasdaq Stock Exchange listing in 2014, most notably its Momo social interaction platform, which makes it easier for people to connect with each other as they identify similar geographical and lifestyle interests (https://ibn.fm/UmWmX). Tantan, one of the country’s top dating platforms, gained wide recognition as “China’s Tinder” (https://ibn.fm/vpnbT), and QOOL Media operates a diversified radio and TV production business (https://ibn.fm/UojBD).

Momo’s operations have allowed it to gather information from its users’ activities to create a comprehensive database of their social interests and match users on the basis of demographics such as age, gender, location, group membership, discussion interests and other social relationships. While helping people to meet based on such interests, the platform’s engine also is able to push advertising content to users based on their interests, with the idea that social context makes business promotion more relevant to users and less of an interruption to their experience.

The global COVID-19 pandemic has had an enormous impact on people’s ability to interact with each other socially, particularly in regions where governments have imposed strict restrictions in an effort to limit the transmission of the highly contagious virus. China was the first country to identify the health emergency, and as such was at the leading edge of experimental efforts to stop the virus’ spread (https://ibn.fm/ctE67).

Social media outlets such as those operated by Momo provide a means of helping people to continue to interact with each other even while separated by such measures. As the company’s multibillion-dollar revenue stream begins to rebound from the pandemic’s economic effects, its mobile applications and hosted recreational activities are enabling users to discover new relationships, expand social connections and build meaningful day-to-day interactions.

The company saw some of its top leadership positions change last year as part of its effort to regroup and rebuild its base, helping to drive a renewed sense of optimism (https://ibn.fm/lP7ji).

For more information on Momo Inc., visit the company’s Investor Relations web page at https://momoinc.gcs-web.com.

• Direct Selling News lists seven key trends shaping the future of direct-selling industry
• Key trends include changes in shopping and work as well as payouts and novel technology such as blockchain and data optimization, faster payments and security
• With many of these aspects built into its core strategy, SHRG seems well-placed to respond to changing market needs

The direct-selling space is fast evolving. A recent article published in “Direct Selling News” highlights seven top trends impacting the speed and direction of that change (https://ibn.fm/dajuy). Operating in the health and wellness direct-selling industry, Sharing Services Global (OTCQB: SHRG) looks well placed to leverage most of those trends and securing a strong position in the new direct-selling era. The article cites Direct Selling Association’s statistics from 2016, showing that as many as 68% of Americans did not like online shopping because they were unable to see, touch or try on the products. However, since then, many aspects of consumer behavior have changed, spurring the movement of consumers to online shopping, including the latest push brought on by the pandemic. Direct-selling companies have adapted to this market change and moved away from high-touch selling format to offer online selling experience through digital tools such as affiliate portals, online shopping carts and replicated websites. These strategic steps have been at the heart of SHRG’s Blue Ocean Strategy. The approach supports the company’s sales force, known as Elepreneurs, in efforts to target today’s consumers in a cost-efficient and direct approach, meeting requirements of a new era centered around social media and a widened consumer base. The timely article also notes that over the past five years direct-selling companies have been reengineering their businesses to focus on digital platforms and establish effective digital channels across the internet and different digital devices such as smartphones and tablets. Since its wholly owned subsidiary Elepreneurs offers a complete virtual business — including a phone app, web system and automated free sampling program — SHRG positions itself as a company fit for the new era where digital is becoming the norm. Elepreneurs also use the interactive, video-based, sales-marketing platform that features proprietary interactive video data collection and analysis technology to provide next-generation lead generation, customer-relationship management and video-marketing software applications. Direct-selling organizations that keep up with the speed of change in consumer behavior and market needs — including shopping trends, workforce requirements, increased payout speed and frequency, data security, and digital design and optimization — will be better equipped to compete and succeed in a rapidly changing market. With its commitment to respond to changing demographics and a strong focus on digital application, SHRG looks well positioned to address the market forces that have been accelerating the change, especially in the post-pandemic era. For more information, visit the company’s websites at www.SHRGInc.com, www.Elevacity.com, or www.Elepreneur.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SRAX’s Sequire has announced that 3 million retail investors are now using its investor intelligence platform
• Sequire’s growth had been predicated on its broad product offering, provision of digital investor–relations tools
• Sequire recently purchased LD Micro, a small and micro-cap company focused platform, to further bolster corporate presence

SRAX (NASDAQ:SRAX), a digital marketing pioneer focused on providing consumer data management services, recently revealed that Sequire, its investor intelligence SaaS platform, had grown to having over 3 million retail investors on its platform (https://ibn.fm/AzKzM). Launched as a stand-alone platform in early 2020, Sequire has seen its growth accelerate at an astounding rate – with the mix of investors and traders currently using its platform rising from 1 million to 3 million in a matter of mere months. The company has also attracted over 91 publicly-listed companies as subscribers on its platform (https://ibn.fm/5ZKtk) – an explosion of growth largely driven by Sequire’s extensive range of services.

Sequire’s popularity has largely predicated on the breadth of its platform and the unique suite of products available to the company’s corporate subscribers. With companies increasingly looking to adopt digital technology and the data generated from such mediums as a way of improving their engagement with investors and stakeholders alike, Sequire has sought to bridge the gap between publicly-listed corporations and their shareholders.

Sequire currently allows its subscribers to track their shareholders’ selling and buying trends, search for and monitor key investors, track outstanding warrants, receive the latest company specific news and media, and even create and send out customized shareholder surveys designed to bring forth their stake-holders’ insights and opinions (https://ibn.fm/0M4BI).

Sequire has sought to further bolster the company’s growth rate via the acquisition of LD Micro, a leading data and event company dedicated towards catering to the small and micro-cap space. Boasting a strong reputation within the listed micro and small-cap corporate universe, LD Micro started life as a newsletter highlighting unique companies—a product offering which would eventually transform into a series of influential corporate conferences, with the events now having firmly entrenched themselves as must-attend occasions for both members of the listed small and micro-cap universe and institutional investors alike.

“We have been discussing the importance of retail investors in public companies since the inception of Sequire,” commented SRAX CEO and founder Christopher Miglino. “It’s the very reason why we built the platform and related tools — to help companies effectively communicate with these investors. The current environment in the capital markets is only validating what we have been preaching for years.”

The company’s management continued to elaborate on the platform’s potential by outlining one example, where a single corporate subscriber using Sequire had witnessed its number of individual shareholders skyrocket from 3,000 to over 360,000 during its tenure on the platform. The high rate of growth would have been largely implausible were it not for Sequire’s investor interaction tools as well as the significant critical mass of investors utilizing the platform.

Over time, big data and artificial intelligence are set to become ever more significant factors governing the development of the investor–relations function – providing issuers with greater insights into their end investors while simultaneously allowing them to personalize their end interactions with the latter group (https://ibn.fm/zhIwX). The recognition of these upcoming changes has underpinned the ongoing development of the Sequire platform, ideally placing it to benefit from the ongoing radical transformation and digitization of the global investor relations industry.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Pure Extracts entered into two large biomass purchase agreements, plans to ramp up production of high-potency THC and CBD extracts in 2021
• Company expects historically low biomass purchase price will produce $590,000 revenue
• Company recently announced DTC eligibility of common shares for increased settlement and clearance speeds, wider access to brokerage firms

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company that focuses on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelics sector, recently entered into two substantial cannabis biomass purchase agreements (https://ibn.fm/Vbyxp) in addition to announcing that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States (https://ibn.fm/BpksL).

“DTC eligibility is a major step forward in increasing liquidity, broadening our shareholder base and building a strong presence for our company within the US capital markets sphere,” said Pure Extracts’ CEO Ben Nikolaevsky. “This is an important step in amplifying our story to a wider audience.”

Along with its new functional mushrooms vertical, Pure Extracts is a leader in the development, production and commercialization of cannabis extracts in Canada, valued by Deloitte at $2.7 billion annually (https://ibn.fm/y1QKv). The company recently announced that it is leveraging historically low cannabis prices by entering into agreements to purchase 220 kilograms of high-potency THC cannabis flower from a large Canadian licensed producer along with 1,000 kilograms of high-potency CBD hemp biomass from a top cultivator in Western Canada.

The company expects to produce full spectrum THC and CBD oils and distillates from the biomass with minimum purities of 66% and 85%, respectively.  The two biomass purchases are expected to yield approximately 70 kilograms of CBD distillate and 25 kilograms of THC distillate with total revenue estimates of $590,000 for both the oil and distillate products based on wholesale prices of $6,000/kg for the CBD biomass and $6,800/kg for the THC biomass.

“Having a stockpile of biomass makes sense for us now as Pure Extracts starts to build its name in the elite category of extractors,” said Nikolaevsky. “We are looking forward to showcasing our world class products and consistently ramping-up revenue this year.”

Pure Extracts recently commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL” and can be found on the Frankfurt Stock Exchange under the WKN number “A2QJAJ”. The company’s common shares are quoted on the U.S. OTC market under the symbol “PRXTF”, and its recent DTC eligibility will enable the company to be cleared and settled at an accelerated rate in addition to increasing access for a wider range of brokerage firms.

Headquartered just north of Whistler Mountain in Pemberton, British Columbia, Pure Extracts is a plant-based extraction company with a focus on cannabis, hemp, functional mushrooms and the emerging psychedelic sector. The company’s all-new, state-of-the-art processing facility is constructed to European Union GMP standards with an aim to export CBD and THC extracts and mushroom products into jurisdictions where sale and consumption are permitted.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Imagin Medical Inc. is a surgical imaging company helping to advance the use of blue light cystoscopy (“BLC”) in battling bladder cancer and reducing costs associated with these procedures
• Bladder cancer is the sixth most prevalent cancer in the United States, and the third most common in men, yet the most expensive to treat While early-stage cancer intervention involves illuminating the bladder with white light – the light that can be seen by the human eye – to visualize and resect tumors, historical use of white light has resulted in incomplete tumor removal and a greater than 50% recurrence rate
• BLC, a revolutionary surgical method using a tumor-staining dye to reveal bladder cancer, has increased the effectiveness of cystoscopy, but financial and functional obstacles have limited its adoption.
• Imagin’s proprietary technology will address these primary barriers., The company’s product is in the manufacturing stage and working toward FDA approval

Increasing patient demand for and clinical data in support  of blue light cystoscopy’s value in detecting to bladder cancer is shining new light on Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, and the potential value of their proprietary technology, the patented i/Blue Imaging System.

New data and analyses presented at the 21st Annual Meeting of the Society of Urologic Oncology in December discussed the budgetary impact of using blue light cystoscopy in surveillance cystoscopies. According to a report on the presentation by Photocure, which markets the tumor-staining drug, Cysview™, for use in blue light applications, the drug didn’t significantly affect the cost of cystoscopies and resulted in finding tumor recurrences that would otherwise have been missed.

“We initiated this study because the utility of blue light cystoscopy (“BLC”) for surveillance in patients receiving BCG (Bacillus Calmette-Guerin immunotherapy) treatments is really not well understood. Thus, no recommendations exist in current guidelines,” stated Dr. Max Kates, assistant professor of Urology and Oncology, and co-director at the Bladder Cancer Multidisplinary Clinic in the The James Buchanan Brady Urologic Institute of Johns Hopkins School of Medicine (https://ibn.fm/ywQGR).

“The use of BLC with Cysview continues to inspire the scientific community as much as ever for improving the care of patients diagnosed with bladder cancer. These new abstracts highlight the role of the procedure throughout patient care, especially focusing on the impact on patient management when used in surveillance,” Photocure President and CEO Dan Schneider added. “The Budget Impact Model supports the favorable cost-benefit of blue light procedures including in the office setting, while reaffirming its superiority in detection of non-muscle-invasive bladder cancer compared to white light alone.”

A Urology Times report (https://ibn.fm/YwotL) noted that the use of BLC with hexaminolevulinate hydrochloride (“HCl”) (under the trade name Cysview) in conjunction with white light during initial transurethral resection of bladder tumors (“TURB”) “lowered costs by $4,660 over 5 years compared with use of white light cystoscopy alone. The investigators also observed that patients receiving BLC had a lower overall cancer burden compared with those receiving white light alone.”

Despite the American Urological Association’s recommendation in favor of using BLC, the technology is used in less than 10 percent of such procedures because of the high cost of equipment and the challenges surgeons face in switching back and forth between white light and blue light images to locate and resect the tumors (https://ibn.fm/yslrQ). And that’s where Imagin Medical comes in.

Imagin’s proprietary i/Blue Imaging (TM) System is compatible with almost any scope already in use by hospitals and surgical centers and enhances their functionality by making it possible for surgeons to see white light and blue light video side-by-side in real time as the bladder tumor resection procedure takes place.

Bladder cancer historically has been the sixth-most common cancer in the United States, one of the most common in men and the most expensive to treat, in part because of a 50 percent recurrence rate that is only exacerbated by surgeons’ inability to always detect and remove all existing tumors using only white light in procedures (https://ibn.fm/BdRjk).

Despite the economic difficulties imposed by the ongoing COVID-19 pandemic, Imagin advanced its technology to development of a working product last year. In 2021, working with Lighthouse Imaging, an FDA certified manufacturer, Imagin has moved to the manufacturing stage to complete pre-production of the i/Blue Imaging System and finalize test parameters to meet exacting FDA requirements (https://ibn.fm/AEglk).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Mental health experts note growing concern over impact of COVID-19 on nation’s mental health
• Compounding stress could have serious health, social consequences
• VTGN offers new hope to those dealing with depression disorders

A new survey from the American Psychological Association (“APA”) shines a spotlight on the growing concern about the impact of the global pandemic on the nation’s mental health (https://ibn.fm/ukaIx). These rising numbers, as well as the treatment for mental health illness and disorders, is of great concern to VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medications that goes beyond the standard of care for anxiety and depression.

Nearly eight in ten adults (78%) report that the coronavirus pandemic is a significant source of stress in their lives, while three in five (60%) say the number of issues America faces is overwhelming to them, according to the “Stress in America(TM) 2020: A National Mental Health Crisis” survey conducted by the Harris Poll on behalf of APA. The survey goes on to note this sobering statistic: Nearly one in five adults (19%) say their mental health is worse than it was at this time last year.

APA CEO Arthur C. Evans Jr. noted that “this survey confirms what many mental health experts have been saying since the start of the pandemic: Our mental health is suffering from the compounding stressors in our lives. This compounding stress will have serious health and social consequences if we don’t act now to reduce it. We’re already seeing this with some of the youngest members of our nation, who just seven months into this crisis are beginning to show signs of serious mental health issues, such as depression and anxiety.”

Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues (https://ibn.fm/vLnl9).  For example, FDA-approved oral antidepressants are slow to act and are associated with significant potential side effects such as anxiety, nausea and vomiting, somnolence and sexual dysfunction.  VistaGen’s PH10 is an innovative pherine nasal spray designed to have rapid-onset therapeutic potential in several neuropsychiatric indications involving depression. Following completion of successful exploratory Phase 2A clinical development, the Company is preparing to launch a planned Phase 2B clinical study of PH10 in major depressive disorder in early 2022. With its rapid-onset pharmacology, potential lack of systemic exposure and favorable safety results observed in all clinical studies to date, PH10 has potential to go beyond the current standard of care for depression as a novel stand-alone treatment for multiple depression disorders.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN